Drug manufacturer Novo Nordisk is giving 340B covered entities refunds for overcharges on two package sizes of its Tresiba FlexTouch insulin pen and on 10 milliliter vials of its Fiasp brand insulin.
The U.S. Health Resources and Services Administration (HRSA) posted the manufacturer’s notice to covered entities on July 23. The overcharges occurred from Q3 2018
Drug manufacturer Novo Nordisk is giving 340B covered entities refunds for overcharges on two package sizes of its Tresiba FlexTouch insulin pen and on 10 milliliter vials of its Fiasp brand insulin.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
